AB Science S.A./€AB
1D1W1MYTD1Y5YMAX
Capital at risk
About AB Science S.A.
AB Science S.A. is a biotechnology company based in Paris, France, specializing in the research, development, and commercialization of protein kinase inhibitors. These are used in the treatment of cancers, chronic inflammatory diseases, and neurodegenerative disorders. Established in 2001, the company targets diseases with significant unmet medical needs through proprietary compounds, notably masitinib which is in various stages of clinical trials. AB Science operates primarily in Europe and has various products in its pipeline aimed at both human and veterinary medicine. Its strategic focus on niche therapeutic areas where there are few treatment options gives it a distinct position in the pharmaceutical industry.
- Ticker
- €AB
- Sector
- Health
- Primary listing
- PAR
- Employees
- 31
- Headquarters
- Paris, France
- Website
- www.ab-science.com
AB Science S.A. Metrics
BasicAdvanced
€56M
-
-€0.03
1.21
-
Price and volume
Market cap
€56M
Beta
1.21
52-week high
€1.70
52-week low
€0.52
Average daily volume
442K
Financial strength
Current ratio
0.959
Quick ratio
0.923
Long term debt to equity
-1.083
Total debt to equity
-1.131
Interest coverage (TTM)
0.50%
Profitability
EBITDA (TTM)
0.745
Gross margin (TTM)
83.30%
Net profit margin (TTM)
-132.62%
Operating margin (TTM)
54.43%
Revenue per employee (TTM)
€40,000
Management effectiveness
Return on assets (TTM)
1.67%
Return on equity (TTM)
7.60%
Valuation
Price to revenue (TTM)
31.167
Price to book
-3
Price to tangible book (TTM)
-2.75
Price to free cash flow (TTM)
-9.445
Free cash flow yield (TTM)
-10.59%
Free cash flow per share (TTM)
-0.075
Growth
Revenue change (TTM)
9.51%
Earnings per share change (TTM)
-80.00%
3-year revenue growth (CAGR)
7.01%
10-year revenue growth (CAGR)
-6.44%
3-year earnings per share growth (CAGR)
-53.06%
10-year earnings per share growth (CAGR)
-27.82%
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.